Summit Therapeutics’ Lung Cancer Drug Under Dark Clouds As Keytruda Challenger Shows Regional Data Differences

All NewsSeptember 8, 2025

Summit’s ivonescimab showed improved survival trends in NSCLC patients with favorable safety, though some results missed statistical significance thresholds.

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Manage consent